Literature DB >> 33574325

Challenges in returning results in a genomic medicine implementation study: the Return of Actionable Variants Empirical (RAVE) study.

David C Kochan1, Erin Winkler2, Noralane Lindor3, Gabriel Q Shaibi4, Janet Olson5, Pedro J Caraballo6, Robert Freimuth5, Joel E Pacyna7, Carmen Radecki Breitkopf7, Richard R Sharp7, Iftikhar J Kullo8.   

Abstract

To inform the process of returning results in genome sequencing studies, we conducted a quantitative and qualitative assessment of challenges encountered during the Return of Actionable Variants Empiric (RAVE) study conducted at Mayo Clinic. Participants (n = 2535, mean age 63 ± 7, 57% female) were sequenced for 68 clinically actionable genes and 14 single nucleotide variants. Of 122 actionable results detected, 118 were returnable; results were returned by a genetic counselor-86 in-person and 12 by phone. Challenges in returning actionable results were encountered in a significant proportion (38%) of the cohort and were related to sequencing and participant contact. Sequencing related challenges (n = 14), affecting 13 participants, included reports revised based on clinical presentation (n = 3); reports requiring corrections (n = 2); mosaicism requiring alternative DNA samples for confirmation (n = 3); and variant re-interpretation due to updated informatics pipelines (n = 6). Participant contact related challenges (n = 44), affecting 38 participants, included nonresponders (n = 20), decedents (n = 1), and previously known results (n = 23). These results should be helpful to investigators preparing for return of results in large-scale genomic sequencing projects.

Year:  2020        PMID: 33574325     DOI: 10.1038/s41525-020-0127-2

Source DB:  PubMed          Journal:  NPJ Genom Med        ISSN: 2056-7944            Impact factor:   8.617


  34 in total

1.  Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients.

Authors:  Jeroen P P Smits; Lars Eckardt; Vincent Probst; Connie R Bezzina; Jean Jacques Schott; Carol Ann Remme; Wilhelm Haverkamp; Günter Breithardt; Denis Escande; Eric Schulze-Bahr; Hervé LeMarec; Arthur A M Wilde
Journal:  J Am Coll Cardiol       Date:  2002-07-17       Impact factor: 24.094

2.  Germline novel MSH2 deletions and a founder MSH2 deletion associated with anticipation effects in HNPCC.

Authors:  A Stella; N C Surdo; P Lastella; D Barana; C Oliani; M G Tibiletti; A Viel; C Natale; A Piepoli; G Marra; G Guanti
Journal:  Clin Genet       Date:  2007-02       Impact factor: 4.438

Review 3.  Stakeholder views on returning research results.

Authors:  Susanne B Haga; Jennifer Q Zhao
Journal:  Adv Genet       Date:  2013       Impact factor: 1.944

4.  MSH2 genomic deletions are a frequent cause of HNPCC.

Authors:  J Wijnen; H van der Klift; H Vasen; P M Khan; F Menko; C Tops; H Meijers Heijboer; D Lindhout; P Møller; R Fodde
Journal:  Nat Genet       Date:  1998-12       Impact factor: 38.330

5.  Integrating Genomics into Healthcare: A Global Responsibility.

Authors:  Zornitza Stark; Lena Dolman; Teri A Manolio; Brad Ozenberger; Sue L Hill; Mark J Caulfied; Yves Levy; David Glazer; Julia Wilson; Mark Lawler; Tiffany Boughtwood; Jeffrey Braithwaite; Peter Goodhand; Ewan Birney; Kathryn N North
Journal:  Am J Hum Genet       Date:  2019-01-03       Impact factor: 11.025

Review 6.  My Approach to the Patient With Familial Hypercholesterolemia.

Authors:  Maya S Safarova; Iftikhar J Kullo
Journal:  Mayo Clin Proc       Date:  2016-06       Impact factor: 7.616

7.  Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families.

Authors:  A Elbaz; J Vale-Santos; K Jurkat-Rott; P Lapie; R A Ophoff; B Bady; T P Links; C Piussan; A Vila; N Monnier
Journal:  Am J Hum Genet       Date:  1995-02       Impact factor: 11.025

8.  Practical implementation issues and challenges for biobanks in the return of individual research results.

Authors:  Marianna J Bledsoe; William E Grizzle; Brian J Clark; Nikolajs Zeps
Journal:  Genet Med       Date:  2012-02-09       Impact factor: 8.822

9.  Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence.

Authors:  Muin J Khoury; Ralph J Coates; James P Evans
Journal:  Genet Med       Date:  2010-11       Impact factor: 8.822

10.  The Return of Actionable Variants Empirical (RAVE) Study, a Mayo Clinic Genomic Medicine Implementation Study: Design and Initial Results.

Authors:  Iftikhar J Kullo; Janet Olson; Xiao Fan; Merin Jose; Maya Safarova; Carmen Radecki Breitkopf; Erin Winkler; David C Kochan; Sara Snipes; Joel E Pacyna; Meaghan Carney; Christopher G Chute; Jyoti Gupta; Sheethal Jose; Eric Venner; Mullai Murugan; Yunyun Jiang; Magdi Zordok; Medhat Farwati; Maraisha Philogene; Erica Smith; Gabriel Q Shaibi; Pedro Caraballo; Robert Freimuth; Noralane M Lindor; Richard Sharp; Stephen N Thibodeau
Journal:  Mayo Clin Proc       Date:  2018-11       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.